Source: Silvercorp Metals.
  • Silvercorp Metals (SVM) has reported production and sales figures for fiscal Q3 2023
  • The quarter included production of 1.9 million ounces of silver, 1,100 ounces of gold, 20.1 million pounds of lead and 7.0 million pounds of zinc
  • These figures represent increases of 1, 0, and 6 per cent YoY, respectively, and a decrease of 13 per cent in zinc YoY
  • Sales results are included below
  • The company expects to release unaudited financial results for the quarter on February 9, 2023 after market close
  • Silvercorp is a Canadian mining company producing silver, gold, lead and zinc in China with a long history of profitability and growth potential
  • Silvercorp Metals (SVM) is up by 0.87 per cent trading at $4.63 per share

Silvercorp Metals (SVM) has reported production and sales figures for fiscal Q3 2023.

The quarter included production of 1.9 million ounces of silver, 1,100 ounces of gold, 20.1 million pounds of lead, and 7.0 million pounds of zinc, representing increases of 1, 0, and 6 per cent YoY, respectively, and a decrease of 13 per cent in zinc YoY.

For the first nine months of fiscal 2023, Silvercorp produced 5.5 million ounces of silver, 3,400 ounces of gold, 57.1 million pounds of lead, and 19.9 million pounds of zinc, representing increases of 10, 17, and 9 per cent YoY, respectively, and a decrease of 12 per cent in zinc YoY.

The company expects to release unaudited financial results for the quarter on February 9, 2023 after market close.

Recent operational results

Silvercorp is a Canadian mining company producing silver, gold, lead and zinc in China with a long history of profitability and growth potential. It holds measured and indicated silver resources of 210.2 million ounces.

Silvercorp Metals (SVM) is up by 0.87 per cent, trading at $4.63 per share as of 11:26 am EST.


More From The Market Online

@ the Bell: TSX recovers and S&P hits fresh high

Energy shares led enough of a rally to overcome industrials and tech losses to push the TSX to a positive end on Tuesday.

Pathologists group accepts Telo Genomics’ test for rare blood cancer

The College of American Pathologists accepts the Telo Genomics' (TSXV:TELO) submission of a test for a rare blood cancer.

Theralase adds cancer immunotherapy to potential revenue streams

Theralase Technologies' (TSXV:TLT) lead drug candidate, Rutherrin, enhanced cancer immunotherapy in a pre-clinical setting.